U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C12H16N2
Molecular Weight 188.2688
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IPIDACRINE

SMILES

NC1=C2CCCCC2=NC3=C1CCC3

InChI

InChIKey=YLUSMKAJIQOXPV-UHFFFAOYSA-N
InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)

HIDE SMILES / InChI

Molecular Formula C12H16N2
Molecular Weight 188.2688
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. Neuromidin has a direct stimulating effect on the conduct of the pulse along the nerve fibers, interneuronal and neuromuscular synapses of the CNS and peripheral nervous system. Pharmacological action neuromidin is based on a combination of two mechanisms of action: blockade of potassium channels of the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses. Neuromidin enhances the effect on smooth muscle acetylcholine not only, but epinephrine, serotonin, histamine and oxytocin. It has the following pharmacological effects: - Improve and stimulate impulse conduction in the nervous system and neuromuscular transmission; - Enhances contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride; - Improves memory, slows progressive course of dementia. In preclinical studies Neuromidin is not teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic action, had no effect on the endocrine system

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.0 µM [IC50]
1000.0 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Neuromidin
Primary
Neuromidin

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Dose and duration of treatment is determined individually depending on the severity of the disease. Peripheral nervous system diseases: 10-20 mg; 1-3 times a day. The treatment is 1 to 2 months. To prevent myasthenic crises, severe violations of neuromuscular conduction briefly parenterally administered 1-2 ml (15-30 mg) Neuromidin 1,5% solution for injection, and then continue treatment tablets Neuromidin, the dose can be increased to 20-40 mg; 5 times a day.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
CV71VTP0VN
Record Status Validated (UNII)
Record Version